![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JR Traynor and SR Nahorski
Department of Cell Physiology and Pharmacology, University of Leicester, UK.
The ability of mu-opioid agonists to activate G proteins has been demonstrated by studying the binding of the GTP analogue guanosine-5'-O- (3-[35S]thio)triphosphate ([35S]GTP gamma S) to membranes from the human neuroblastoma SH-SY5Y cell line. The potent opioid agonist fentanyl caused an approximate doubling of basal [35S]GTP gamma S binding in a naloxone-sensitive manner, confirming this to be an opioid receptor-mediated process. The presence of GDP was necessary to observe this effect. Pretreatment of the cells with pertussis toxin (100 ng/ml, for 24 hr) completely prevented the fentanyl-stimulated increase in [35S]GTP gamma S binding and lowered the basal binding of [35S]GTP gamma S. These latter data suggest an involvement of Gi and/or Go proteins and their activation by added membrane-bound receptors even in the absence of agonist. The order of potency of a series of opioid agonists in stimulating the binding of [35S]GTP gamma S was buprenorphine > cyclazocine = levallorphan > nalorphine > [D- Ala2,MePhe4,Gly-ol5]enkephalin (DAMGO) > fentanyl > morphine > pentazocine. DAMGO, fentanyl, and morphine were full agonists but the remaining compounds showed decreasing levels of intrinsic activity in the order buprenorphine > pentazocine > cyclazocine = nalorphine > levallorphan. The opioid antagonist naloxone was without effect. Under the conditions of the [35S]GTP gamma S assay, binding of agonists was to a high affinity site, indicating that a high agonist affinity state of the mu-opioid receptor is responsible for the observed stimulation of [35S]GTP gamma S binding. The level of [35S]GTP gamma S binding (597 fmol/mg of protein) stimulated by DAMGO was 2-fold greater than the maximal number of mu-opioid agonist binding sites (Bmax) determined using [3H]DAMGO (254 fmol/mg of protein). The opioid agonist-mediated stimulation of [35S]GTP gamma S binding in SH-SY5Y cell membranes thus provides a "functional" measure of agonist occupation of mu-opioid receptors and offers a simple method for the determination of efficacy and intrinsic activity of mu-opioid agonists.
This article has been cited by other articles:
|
|
 |
|
  V. O. Nikolaev, C. Boettcher, C. Dees, M. Bunemann, M. J. Lohse, and M. H. Zenk Live Cell Monitoring of {micro}-Opioid Receptor-mediated G-protein Activation Reveals Strong Biological Activity of Close Morphine Biosynthetic Precursors J. Biol. Chem., September 14, 2007; 282(37): 27126 - 27132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pinal-Seoane, I. R. Martin, V. Gonzalez-Nunez, E. M. F. de Velasco, F. A. Alvarez, R. G. Sarmiento, and R. E Rodriguez Characterization of a new duplicate {delta}-opioid receptor from zebrafish J. Mol. Endocrinol., December 1, 2006; 37(3): 391 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Clark, C. A. Furman, T. D. Gilson, and J. R. Traynor Comparison of the Relative Efficacy and Potency of {micro}-Opioid Agonists to Activate G{alpha}i/o Proteins Containing a Pertussis Toxin-Insensitive Mutation J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 858 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Peckham and J. R. Traynor Comparison of the Antinociceptive Response to Morphine and Morphine-Like Compounds in Male and Female Sprague-Dawley Rats J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1195 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. H. Ko, M. F. Divin, H. Lee, J. H. Woods, and J. R. Traynor Differential in Vivo Potencies of Naltrexone and 6beta-Naltrexol in the Monkey J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 772 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Ciraulo, R. J. Hitzemann, E. Somoza, C. M. Knapp, J. Rotrosen, O. Sarid-Segal, A. M. Ciraulo, D. J. Greenblatt, and C. N. Chiang Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials J. Clin. Pharmacol., February 1, 2006; 46(2): 179 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Talbot, H. K. Happe, and L. C. Murrin {micro} Opioid Receptor Coupling to Gi/o Proteins Increases during Postnatal Development in Rat Brain J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 596 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gaspar, E. Ducza, A. Mihalyi, A. Marki, Z. Kolarovszki-Sipiczki, E. Paldy, S. Benyhe, A. Borsodi, I. Foldesi, and G. Falkay Pregnancy-induced decrease in the relaxant effect of terbutaline in the late-pregnant rat myometrium: role of G-protein activation and progesterone Reproduction, July 1, 2005; 130(1): 113 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. O'Connor, L. J. Porrino, H. M. L. Davies, and S. R. Childers Time-Dependent Changes in Receptor/G-Protein Coupling in Rat Brain following Chronic Monoamine Transporter Blockade J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 510 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Clark and J. R. Traynor Endogenous Regulator of G Protein Signaling Proteins Reduce {micro}-Opioid Receptor Desensitization and Down-Regulation and Adenylyl Cyclase Tolerance in C6 Cells J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 809 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. BASAVARAJAPPA and B. L. HUNGUND ROLE OF THE ENDOCANNABINOID SYSTEM IN THE DEVELOPMENT OF TOLERANCE TO ALCOHOL Alcohol Alcohol., January 1, 2005; 40(1): 15 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, K. Tang, S. Inan, D. Siebert, U. Holzgrabe, D. Y.W. Lee, P. Huang, J.-G. Li, A. Cowan, and L.-Y. Liu-Chen Comparison of Pharmacological Activities of Three Distinct {kappa} Ligands (Salvinorin A, TRK-820 and 3FLB) on {kappa} Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 220 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Walker, M. J. Picker, A. Granger, and L. A. Dykstra Effects of Opioids in Morphine-Treated Pigeons Trained to Discriminate among Morphine, the Low-Efficacy Agonist Nalbuphine, and Saline J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 150 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Thompson, H. Wojno, E. Greiner, E. L. May, K. C. Rice, and D. E. Selley Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at {micro}- and {delta}-Opioid Receptors J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 547 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pattee, A.-E. Ilie, S. Benyhe, G. Toth, A. Borsodi, and S. R. Nagalla Cloning and Characterization of Xen-dorphin Prohormone from Xenopus laevis: A NEW OPIOID-LIKE PROHORMONE DISTINCT FROM PROENKEPHALIN AND PRODYNORPHIN J. Biol. Chem., December 26, 2003; 278(52): 53098 - 53104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Allen, A. L. Granger, and L. A. Dykstra The Competitive N-Methyl-D-aspartate Receptor Antagonist (-)-6-Phosphonomethyl-deca-hydroisoquinoline-3-carboxylic Acid (LY235959) Potentiates the Antinociceptive Effects of Opioids That Vary in Efficacy at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 785 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zollner, M. A. Shaqura, C. P. Bopaiah, S. Mousa, C. Stein, and M. Schafer Painful Inflammation-Induced Increase in {micro}-Opioid Receptor Binding and G-Protein Coupling in Primary Afferent Neurons Mol. Pharmacol., August 1, 2003; 64(2): 202 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. H. Ko, H. Lee, C. Harrison, M. J. Clark, H. F. Song, N. N. Naughton, J. H. Woods, and J. R. Traynor Studies of {micro}-, {kappa}-, and {delta}-Opioid Receptor Density and G Protein Activation in the Cortex and Thalamus of Monkeys J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 179 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Barrett, E. S. Smith, and M. J. Picker Use of Irreversible Antagonists to Determine the Relative Efficacy of {micro}-Opioids in a Pigeon Drug Discrimination Procedure: Comparison of {beta}-Funaltrexamine and Clocinnamox J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1061 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Borgland, M. Connor, P. B. Osborne, J. B. Furness, and M. J. Christie Opioid Agonists Have Different Efficacy Profiles for G Protein Activation, Rapid Desensitization, and Endocytosis of Mu-opioid Receptors J. Biol. Chem., May 23, 2003; 278(21): 18776 - 18784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Sterious and E. A. Walker Potency Differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an Antagonist of Peptide and Alkaloid {micro}-Agonists in an Antinociception Assay J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 301 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fabian, B. Bozo, M. Szikszay, G. Horvath, C. J. Coscia, and M. Szucs Chronic Morphine-Induced Changes in {micro}-Opioid Receptors and G Proteins of Different Subcellular Loci in Rat Brain J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 774 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Traynor, M. J. Clark, and A. E. Remmers Relationship between Rate and Extent of G Protein Activation: Comparison between Full and Partial Opioid Agonists J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 157 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Vogt, L. J. Sim-Selley, S. R. Childers, R. G. Wiley, and B. A. Vogt Colocalization of {micro}-Opioid Receptors and Activated G-Proteins in Rat Cingulate Cortex J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 840 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Inoue, S. Matsunaga, M. H. Rashid, A. Yoshida, K. Mizuno, T. Sakurada, H. Takeshima, and H. Ueda Pronociceptive Effects of Nociceptin/Orphanin FQ (13-17) at Peripheral and Spinal Level in Mice J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 213 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Butelman, M. C. H. Ko, J. R. Traynor, J. A. Vivian, M.-J. Kreek, and J. H. Woods GR89,696: A Potent kappa -Opioid Agonist with Subtype Selectivity in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1049 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Hall, J. Liu, A. A. F. Sima, and J. W. Wiley Impaired Inhibitory G-Protein Function Contributes to Increased Calcium Currents in Rats With Diabetic Neuropathy J Neurophysiol, August 1, 2001; 86(2): 760 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Alt, I. J. McFadyen, C. D. Fan, J. H. Woods, and J. R. Traynor Stimulation of Guanosine-5'-O-(3-[35S]thio)triphosphate Binding in Digitonin-Permeabilized C6 Rat Glioma Cells: Evidence for an Organized Association of {micro}-Opioid Receptors and G Protein J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 116 - 121. [Abstract] [Full Text]
|
|
|
|
|
|
P. Huang, G. B. Kehner, A. Cowan, and L.-Y. Liu-Chen Comparison of Pharmacological Activities of Buprenorphine and Norbuprenorphine: Norbuprenorphine Is a Potent Opioid Agonist J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 688 - 695. [Abstract] [Full Text]
|
|
|
|
|
|
I. J. McFadyen, K. Sobczyk-Kojiro, M. J. Schaefer, J. C. Ho, J. R. Omnaas, H. I. Mosberg, and J. R. Traynor Tetrapeptide Derivatives of [D-Pen2,D-Pen5]-Enkephalin (DPDPE) Lacking an N-Terminal Tyrosine Residue Are Agonists at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 960 - 966. [Abstract] [Full Text]
|
|
|
|
|
|
I. J. McFadyen, H. Houshyar, L.-Y. Liu-Chen, J. H. Woods, and J. R. Traynor The Steroid 17alpha -Acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3,5-dien-20-one (SC17599) Is a Selective {micro}-Opioid Agonist: Implications for the {micro}-Opioid Pharmacophore Mol. Pharmacol., October 1, 2000; 58(4): 669 - 676. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Broadbear, T. L. Sumpter, T. F. Burke, S. M Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor Methocinnamox Is a Potent, Long-Lasting, and Selective Antagonist of Morphine-Mediated Antinociception in the Mouse: Comparison with Clocinnamox, beta -Funaltrexamine, and beta -Chlornaltrexamine J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 933 - 940. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Broom, L. Guo, A. Coop, S. M. Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor BU48: A Novel Buprenorphine Analog That Exhibits delta -Opioid-Mediated Convulsions but Not delta -Opioid-Mediated Antinociception in Mice J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1195 - 1200. [Abstract] [Full Text]
|
|
|
|
|
|
H. Berger, G. Calo', E. Albrecht, R. Guerrini, and M. Bienert [Nphe1]NC(1-13)NH2 Selectively Antagonizes Nociceptin/Orphanin FQ-Stimulated G-Protein Activation in Rat Brain J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 428 - 433. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. J. Sim-Selley, D. E. Selley, L. J. Vogt, S. R. Childers, and T. J. Martin Chronic Heroin Self-Administration Desensitizes {micro} Opioid Receptor-Activated G-Proteins in Specific Regions of Rat Brain J. Neurosci., June 15, 2000; 20(12): 4555 - 4562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Chen and A. J. Lawrence Effect of Chronic Ethanol and Withdrawal on the {micro}-Opioid Receptor- and 5-Hydroxytryptamine1A Receptor-Stimulated Binding of [35S]Guanosine-5'-O-(3-thio)triphosphate in the Fawn-Hooded Rat Brain: A Quantitative Autoradiography Study J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 159 - 165. [Abstract] [Full Text]
|
|
|
|
|
|
G. L. Fraser, J. Holmgren, P. B. S. Clarke, and C. Wahlestedt Antisense Inhibition of delta -Opioid Receptor Gene Function In Vivo by Peptide Nucleic Acids Mol. Pharmacol., April 1, 2000; 57(4): 725 - 731. [Abstract] [Full Text]
|
|
|
|
|
|
B. L. Hungund and B. S. Basavarajappa ARE ANANDAMIDE AND CANNABINOID RECEPTORS INVOLVED IN ETHANOL TOLERANCE? A REVIEW OF THE EVIDENCE Alcohol Alcohol., March 1, 2000; 35(2): 126 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Zaki, D. E. Keith Jr., G. A. Brine, F. I. Carroll, and C. J. Evans Ligand-Induced Changes in Surface {micro}-Opioid Receptor Number: Relationship to G Protein Activation? J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1127 - 1134. [Abstract] [Full Text]
|
|
|
|
|
|
J. R. Traynor, L. Guo, A. Coop, J. W. Lewis, and J. H. Woods Ring-Constrained Orvinols as Analogs of Buprenorphine: Differences in Opioid Activity Related to Configuration of C20 Hydroxyl Group J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1093 - 1099. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. B. Slot and F. C. Colpaert Opiate States of Memory: Receptor Mechanisms J. Neurosci., December 1, 1999; 19(23): 10520 - 10529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhao, L.-H. Ben, Y.-L. Wu, W. Hu, K. Ling, S.-M. Xin, H.-L. Nie, L. Ma, and G. Pei Anti-HIV Agent Trichosanthin Enhances the Capabilities of Chemokines to Stimulate Chemotaxis and G Protein Activation, and This Is Mediated through Interaction of Trichosanthin and Chemokine Receptors J. Exp. Med., July 5, 1999; 190(1): 101 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Happe, D. B. Bylund, and L. C. Murrin Alpha-2 Adrenergic Receptor Functional Coupling to G Proteins in Rat Brain During Postnatal Development J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1134 - 1142. [Abstract] [Full Text]
|
|
|
|
|
|
A. E. Remmers, M. J. Clark, A. Mansour, H. Akil, J. H. Woods, and F. Medzihradsky Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Human Kappa Opioid Receptor J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 827 - 833. [Abstract] [Full Text]
|
|
|
|
|
|
C. S. Breivogel, D. E. Selley, and S. R. Childers Cannabinoid Receptor Agonist Efficacy for Stimulating [35S]GTPgamma S Binding to Rat Cerebellar Membranes Correlates with Agonist-induced Decreases in GDP Affinity J. Biol. Chem., July 3, 1998; 273(27): 16865 - 16873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Alt, A. Mansour, H. Akil, F. Medzihradsky, J. R. Traynor, and J. H. Woods Stimulation of Guanosine-5'-O-(3-[35S]Thio)Triphosphate Binding by Endogenous Opioids Acting at a Cloned Mu Receptor J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 282 - 288. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Fukushima, Y. Kimura, and J. Chun A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid PNAS, May 26, 1998; 95(11): 6151 - 6156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Selley, Q. Liu, and S. R. Childers Signal Transduction Correlates of Mu Opioid Agonist Intrinsic Efficacy: Receptor-Stimulated [35S]GTPgamma S Binding in mMOR-CHO Cells and Rat Thalamus J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 496 - 505. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. S. Gembitsky, S. Lovas, and R. F. Murphy Development of a High Throughput Functional Assay for Structure-Activity Studies of Neurokinin A Analogs J Biomol Screen, April 1, 1998; 3(3): 183 - 188. [Abstract] [PDF]
|
|
|
|
|
|
G.-H. Fan, J. Zhao, Y.-L. Wu, L.-G. Lou, Z. Zhang, Q. Jing, L. Ma, and G. Pei N-Methyl-D-Aspartate Attenuates Opioid Receptor-Mediated G Protein Activation and This Process Involves Protein Kinase C Mol. Pharmacol., April 1, 1998; 53(4): 684 - 690. [Abstract] [Full Text]
|
|
|
|
 |
|
 F Berrendero, L Garcia-Gil, M. Hernandez, J Romero, M Cebeira, R de Miguel, J. Ramos, and J. Fernandez-Ruiz Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development Development, January 8, 1998; 125(16): 3179 - 3188. [Abstract] [PDF]
|
|
|
|
|
|
P. G. Szekeres and J. R. Traynor Delta Opioid Modulation of the Binding of Guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 Cell Membranes: Characterization of Agonist and Inverse Agonist Effects J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1276 - 1284. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Clark, P. J. Emmerson, A. Mansour, H. Akil, J. H. Woods, P. S. Portoghese, A. E. Remmers, and F. Medzihradsky Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Delta Opioid Receptor J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 501 - 510. [Abstract] [Full Text]
|
|
|
|
|
|
C. T. Dooley, C. G. Spaeth, I. P. Berzetei-Gurske, K. Craymer, I. D. Adapa, S. R. Brandt, R. A. Houghten, and L. Toll Binding and In Vitro Activities of Peptides with High Affinity for the Nociceptin/Orphanin FQ Receptor, ORL1 J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 735 - 741. [Abstract] [Full Text]
|
|
|
|
|
|
C. Waeber and M. A. Moskowitz 5-Hydroxytryptamine1A and 5-Hydroxytryptamine1B Receptors Stimulate [35S]Guanosine-5'-O-(3-thio)triphosphate Binding to Rodent Brain Sections as Visualized by In Vitro Autoradiography Mol. Pharmacol., October 1, 1997; 52(4): 623 - 631. [Abstract] [Full Text]
|
|
|
|
|
|
C. S. Breivogel, L. J. Sim, and S. R. Childers Regional Differences in Cannabinoid Receptor/G-protein Coupling in Rat Brain J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1632 - 1642. [Abstract] [Full Text]
|
|
|
|
|
|
J. Zhu, L.-Y. Luo, J.-G. Li, C. Chen, and L.-Y. Liu-Chen Activation of the Cloned Human Kappa Opioid Receptor by Agonists Enhances [35S]GTPgamma S Binding to Membranes: Determination of Potencies and Efficacies of Ligands J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 676 - 684. [Abstract] [Full Text]
|
|
|
|
|
|
A. Newman-Tancredi, V. Audinot, C. Chaput, and L.V. a. M. J. Millan [35S]Guanosine-5'-O-(3-thio)triphosphate Binding as a Measure of Efficacy at Human Recombinant Dopamine D4.4 Receptors: Actions of Antiparkinsonian and Antipsychotic Agents J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 181 - 191. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Williams, A. D. Michel, W. Feniuk, and P. P. A. Humphrey Somatostatin5 Receptor-Mediated [35S]Guanosine-5'-O-(3-thio)triphosphate Binding: Agonist Potencies and the Influence of Sodium Chloride on Intrinsic Activity Mol. Pharmacol., June 1, 1997; 51(6): 1060 - 1069. [Abstract] [Full Text]
|
|
